Breast Neoplasms
Conditions
Brief summary
1. To construct a prospective, multi-center breast cancer treatment cohort in China, and analyze the factors affecting breast cancer diagnosis and treatment. 2. To evaluate the diagnosis and treatment and prognosis of breast cancer among patients in different regions and hospitals.
Detailed description
This research aims to: A. Understand and analyze the current status of breast cancer diagnosis and treatment; B. Publish an annual report on diagnosis and treatment; C. Data sharing, dynamic evaluation; D. Evaluate consensus and guideline promotion and implementation effects; E. Propose and set clinical quality standards for industry associations, and propose improvement goals; F. Provide a basis for industry associations to formulate specialized training programs; G. To provide assistance in the formulation of health insurance policies; H. Provide a platform for clinical research on breast cancer; I. Provide evidence for the formulation of clinical guidelines and consensus
Interventions
PROCEDUREThe study did not involve intervention in the patient's treatment regimen
This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China.
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with malignant breast tumors must be diagnosed by cytology or histology, and their pathological types include but are not limited to breast carcinoma in situ, invasive carcinoma, and breast sarcoma.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The current status of patients diagnosed with breast cancer and their types of treatment | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Including but not limited to the patient receiving different surgical methods, different drugs, neoadjuvant and adjuvant therapy, etc. |
| Prognostic outcomes of patients | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Including patient disease-free survival and overall survival. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prognosis-recurrence-free survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | The time from the diagnosis of breast cancer to the recurrence or metastasis of the patient, and the parts involved. |
| Prognosis-overall survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | As the time from diagnosis of breast cancer to death of the patient |
Countries
China
Contacts
Primary ContactJiong Wu, M.D
Outcome results
None listed